Cogent Biosciences (COGT) vs Kiniksa Pharmaceuticals International (KNSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kiniksa Pharmaceuticals International (KNSA) has outperformed Cogent Biosciences (COGT) over the past year, gaining 105.6% versus a gain of 93.1%. Over five years, KNSA leads with a +587.8% price change compared with +225.5% for COGT. Kiniksa Pharmaceuticals International is the larger company by market cap ($6.14 billion vs $5.22 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COGT | KNSA |
|---|---|---|
| Share price | $30.08 | $78.75 |
| Market cap | $5.22B | $6.14B |
| 1-day change | -0.20% | +1.01% |
| YTD return | -15.32% | +90.91% |
| 1-year return | +93.07% | +105.56% |
| 5-year return | +225.54% | +587.77% |
| P/E ratio (TTM) | — | 79.55 |
| Forward P/E | — | 48.69 |
| EPS (TTM) | $-2.16 | $0.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $677.56M |
| Revenue growth (YoY) | — | +60.09% |
| Net income (latest FY) | $-328.94M | $59.01M |
| Gross margin | — | 88.54% |
| Operating margin | — | 11.40% |
| Net margin | — | 8.71% |
| 52-week high | $43.73 | $82.94 |
| 52-week low | $13.78 | $35.20 |
| Distance from 52-week high | -31.21% | -5.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +85.57% | +24.44% |
| Average volume | 1.90M | 578.96K |
| Shares outstanding | 173.52M | 48.29M |
| Employees | 258 | 366 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KNSA has outperformed COGT by 12.5 percentage points over the past year.
- The two companies sit in different sectors: Cogent Biosciences in Healthcare and Kiniksa Pharmaceuticals International in Health Care.
About Cogent Biosciences
COGT stock →Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Healthcare · Biotechnology · 258 employees
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
COGT vs KNSA FAQ
Which is bigger, Cogent Biosciences or Kiniksa Pharmaceuticals International?
Kiniksa Pharmaceuticals International (KNSA) is larger, with a market capitalization of $6.14B compared with $5.22B for Cogent Biosciences (COGT).
Which stock has performed better over the past year, COGT or KNSA?
KNSA returned +105.56% over the past 12 months, compared with +93.07% for COGT (price return, excluding dividends). Past performance does not predict future results.
Are Cogent Biosciences and Kiniksa Pharmaceuticals International in the same industry?
No. Cogent Biosciences is in the Healthcare sector, while Kiniksa Pharmaceuticals International is in Health Care.